Michael P Coleman (Michael Coleman)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Topics

Pluripotent Stem Cells

Subarachnoid Hemorrhage

Top Venues

Nature communications

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Nature reviews. Neuroscience

This page only lists publications with an associated author ORCID identifier.

Publications

James R Tribble, Melissa Jöe, Carmine Varricchio, Amin Otmani, Alessio Canovai, Baninia Habchi, Evangelia Daskalakis, Romanas Chaleckis, Andrea Loreto, Jonathan Gilley, Craig E Wheelock, Gauti Jóhannesson, Raymond Ching-Bong Wong, Michael P Coleman, Andrea Brancale, Pete A Williams
NMNAT2 is a druggable target to drive neuronal NAD production. Nature communications 15 (1) (2024)
James R Tribble, Melissa Jöe, Carmine Varricchio, Amin Otmani, Alessio Canovai, Baninia Habchi, Evangelia Daskalakis, Romanas Chaleckis, Andrea Loreto, Jonathan Gilley, Craig E Wheelock, Gauti Jóhannesson, Raymond Ching-Bong Wong, Michael P Coleman, Andrea Brancale, Pete A Williams
Author Correction: NMNAT2 is a druggable target to drive neuronal NAD production. Nature communications 15 (1) (2024)
James R Tribble, Melissa Jöe, Carmine Varricchio, Amin Otmani, Alessio Canovai, Baninia Habchi, Evangelia Daskalakis, Romanas Chaleckis, Andrea Loreto, Jonathan Gilley, Craig E Wheelock, Gauti Jóhannesson, Raymond Ching-Bong Wong, Michael P Coleman, Andrea Brancale, Pete A Williams
NMNAT2 is a druggable target to drive neuronal NAD production. Nature communications 15 (1) (2024)
James R Tribble, Melissa Jöe, Carmine Varricchio, Amin Otmani, Alessio Canovai, Baninia Habchi, Evangelia Daskalakis, Romanas Chaleckis, Andrea Loreto, Jonathan Gilley, Craig E Wheelock, Gauti Jóhannesson, Raymond Ching-Bong Wong, Michael P Coleman, Andrea Brancale, Pete A Williams
NMNAT2 is a druggable target to drive neuronal NAD production. Nature communications 15 (1) (2024)
Janos Groh, Tassnim Abdelwahab, Yogita Kattimani, Michaela Hörner, Silke Loserth, Viktoria Gudi, Robert Adalbert, Fabian Imdahl, Antoine-Emmanuel Saliba, Michael P Coleman, Martin Stangel, Mikael Simons, Rudolf Martini
Microglia-mediated demyelination protects against CD8 + T cell-driven axon degeneration in mice carrying PLP defects. Nature communications 14 (1) (2023)
Michael P Coleman
Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 19 (4) (2022)
Michael P Coleman, Ahmet Hoke
Programmed axon degeneration: from mouse to mechanism to medicine. Nature reviews. Neuroscience 21 (4) (2020)